George Lin, MD
Interventional Cardiology · Bellflower, CANPI 1205153913
Payments from drug & device makers
Across 269 payments — averaging $34.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abbott$1K
- Medtronic$857
- Novartis$653
- Edwards Lifesciences$568
- AstraZeneca$486
- plus $3K from 32 others
What the payments were for
- Food & beverage$9,197100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 41 | $1,958 |
| Abbott | 22 | $1,258 |
| Medtronic(2 entities) | 18 | $857 |
| Novartis | 40 | $653 |
| Edwards Lifesciences | 9 | $568 |
| AstraZeneca | 5 | $486 |
| Amgen | 21 | $423 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $313 |
| E.r. Squibb & Sons, L.L.C. | 8 | $269 |
| Abiomed | 4 | $266 |
| Pfizer | 20 | $257 |
| GSK | 2 | $246 |
| Johnson & Johnson | 9 | $172 |
| Amarin Pharma, Inc. | 9 | $160 |
| Nestle Healthcare Nutrition Inc. | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Chiesi USA, Inc. | 6 | $125 |
| Cardiovascular Systems Inc. | 3 | $95 |
| Shockwave Medical, Inc | 4 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| Nuwellis, Inc. | 1 | $76 |
| Akcea Therapeutics, Inc. | 3 | $74 |
| Braemar Manufacturing, LLC | 1 | $70 |
| Teva Pharmaceuticals USA, Inc. | 1 | $63 |
| Irhythm Technologies, Inc. | 3 | $62 |
| Lundbeck LLC | 2 | $46 |
| Cardiva Medical, Inc. | 1 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| GE HealthCare | 2 | $31 |
| Bayer | 1 | $28 |
| Acist Medical Systems, Inc. | 2 | $27 |
| Cardinal Health 200 LLC | 1 | $25 |
| Silk Road Medical, Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $13 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience Sierra Coronary Stent System$551
- Micra$534
- Edwards SAPIEN 3 Transcatheter Heart Valve$416
- GENERAL ATHERECTOMY$405
- FARXIGA$371
- AVVIGO Guidance System$285
- JOT DX$215
- Impella$172
- GENERAL - THERAPIES$168
- COMET$129
- ZENPEP$125
- NEXLIZET$125
- NEXLETOL$125
- AREXVY$124
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$117
- Repatha$115
- Confirm Rx$110
- LUX-DX$110
- SQ RX PULSE GENERATOR$104
- GENERAL - STRUCTURAL HEART$104
How this compares
$9,203 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 54 | $56,244 |
| PradaxaDabigatran Etexilate Mesylate | 191 | $39,029 |
| EntrestoSacubitril/Valsartan | 58 | $36,480 |
| BrilintaTicagrelor | 19 | $15,576 |
| JardianceEmpagliflozin | 12 | $4,446 |
| Bisoprolol Fumarate | 109 | $2,663 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $1,648 |
| Atorvastatin Calcium | 75 | $983 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $868 |
| Losartan Potassium | 63 | $711 |
| Metoprolol Tartrate | 55 | $584 |
| Carvedilol | 53 | $569 |
| ClopidogrelClopidogrel Bisulfate | 29 | $554 |
| Lisinopril | 45 | $532 |
| Furosemide | 41 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $257 | $56,24454 claims |
| Boehringer IngelheimPradaxa, Jardiance | $16 | $43,475203 claims |
| NovartisEntresto | $653 | $36,48058 claims |
| AstraZenecaBrilinta | $486 | $15,57619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Bellflower
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.